Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status (Ascending)
00078-0594-51 00078-0594 Everolimus Afinitor 2.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral July 9, 2010 In Use
00078-0594-61 00078-0594 Everolimus Afinitor 2.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral July 9, 2010 In Use
00078-0620-51 00078-0620 Everolimus Afinitor 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral July 29, 2011 In Use
00078-0620-61 00078-0620 Everolimus Afinitor 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral July 29, 2011 In Use
00078-0626-51 00078-0626 Everolimus Afinitor 2.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Aug. 29, 2012 In Use
00078-0626-61 00078-0626 Everolimus Afinitor 2.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Aug. 29, 2012 In Use
00078-0627-51 00078-0627 Everolimus Afinitor 3.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Aug. 29, 2012 In Use
00078-0627-61 00078-0627 Everolimus Afinitor 3.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Aug. 29, 2012 In Use
00078-0628-51 00078-0628 Everolimus Afinitor 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Aug. 29, 2012 In Use
00078-0628-61 00078-0628 Everolimus Afinitor 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Aug. 29, 2012 In Use
00078-0668-15 00078-0668 Trametinib Mekinist 2.0 mg/1 Chemotherapy MEK Inhibitor BRAF Oral March 17, 2016 April 30, 2024 In Use
00078-0669-13 00078-0669 Ofatumumab Arzerra 20.0 mg/mL Immunotherapy Monoclonal Antibody CD20 Intravenous Feb. 1, 2016 In Use
00078-0669-61 00078-0669 Ofatumumab Arzerra 20.0 mg/mL Immunotherapy Monoclonal Antibody CD20 Intravenous Feb. 1, 2016 In Use
00078-0669-84 00078-0669 Ofatumumab Arzerra 20.0 mg/mL Immunotherapy Monoclonal Antibody CD20 Intravenous Feb. 1, 2016 Feb. 1, 2016 In Use
00078-0670-66 00078-0670 Pazopanib Hydrochloride Votrient 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, KIT, Lck, FMS Oral July 12, 2016 Oct. 31, 2024 In Use
00078-0698-02 00078-0698 RYDAPT Rydapt 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FLT3 Oral April 28, 2017 In Use
00078-0698-19 00078-0698 RYDAPT Rydapt 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FLT3 Oral April 28, 2017 In Use
00078-0698-51 00078-0698 RYDAPT Rydapt 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FLT3 Oral April 28, 2017 In Use
00078-0698-99 00078-0698 RYDAPT Rydapt 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FLT3 Oral April 28, 2017 In Use
00078-0709-56 00078-0709 Capmatinib TABRECTA 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor MET Oral May 6, 2020 In Use
00078-0709-94 00078-0709 Capmatinib TABRECTA 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor MET Oral May 6, 2020 In Use
00078-0716-56 00078-0716 Capmatinib TABRECTA 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor MET Oral May 6, 2020 In Use
00078-0716-94 00078-0716 Capmatinib TABRECTA 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor MET Oral May 6, 2020 In Use
00078-0867-14 00078-0867 Ribociclib Kisqali 200.0 mg/1, 200.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral March 13, 2017 In Use
00078-0867-42 00078-0867 Ribociclib Kisqali 200.0 mg/1, 200.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral March 13, 2017 In Use
00078-0874-21 00078-0874 Ribociclib Kisqali 200.0 mg/1, 200.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral March 13, 2017 In Use
00078-0874-63 00078-0874 Ribociclib Kisqali 200.0 mg/1, 200.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral March 13, 2017 In Use
00085-1366-01 00085-1366 Temozolomide Temodar 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 11, 1999 May 29, 2015 In Use
00085-1366-02 00085-1366 Temozolomide Temodar 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 11, 1999 May 29, 2015 In Use
00085-1366-03 00085-1366 Temozolomide Temodar 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 11, 1999 In Use
00085-1366-04 00085-1366 Temozolomide Temodar 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 11, 1999 In Use
00085-1366-05 00085-1366 Temozolomide Temodar 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Nov. 2, 2012 In Use
00085-1417-01 00085-1417 Temozolomide Temodar 250.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 11, 1999 Oct. 22, 2014 In Use
00085-1417-02 00085-1417 Temozolomide Temodar 250.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 11, 1999 In Use
00085-1417-03 00085-1417 Temozolomide Temodar 250.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Nov. 2, 2012 In Use
00085-1425-01 00085-1425 Temozolomide Temodar 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 11, 1999 Oct. 22, 2014 In Use
00085-1425-02 00085-1425 Temozolomide Temodar 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 11, 1999 Oct. 22, 2014 In Use
00085-1425-03 00085-1425 Temozolomide Temodar 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 11, 1999 In Use
00085-1425-04 00085-1425 Temozolomide Temodar 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 11, 1999 In Use
00085-1425-05 00085-1425 Temozolomide Temodar 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Nov. 2, 2012 In Use
00085-1430-01 00085-1430 Temozolomide Temodar 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 11, 1999 May 29, 2015 In Use
00085-1430-02 00085-1430 Temozolomide Temodar 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 11, 1999 May 29, 2015 In Use
00085-1430-03 00085-1430 Temozolomide Temodar 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 11, 1999 In Use
00085-1430-04 00085-1430 Temozolomide Temodar 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 11, 1999 In Use
00085-1430-05 00085-1430 Temozolomide Temodar 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Nov. 2, 2012 In Use
00085-1519-01 00085-1519 Temozolomide Temodar 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 11, 1999 Oct. 22, 2014 In Use
00085-1519-02 00085-1519 Temozolomide Temodar 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 11, 1999 Oct. 22, 2014 In Use
00085-1519-03 00085-1519 Temozolomide Temodar 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 11, 1999 In Use
00085-1519-04 00085-1519 Temozolomide Temodar 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 11, 1999 In Use
00085-1519-05 00085-1519 Temozolomide Temodar 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Nov. 2, 2012 In Use
00085-3004-01 00085-3004 Temozolomide Temodar 5.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 11, 1999 Oct. 22, 2014 In Use
00085-3004-02 00085-3004 Temozolomide Temodar 5.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 11, 1999 Oct. 22, 2014 In Use
00085-3004-03 00085-3004 Temozolomide Temodar 5.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 11, 1999 In Use
00085-3004-04 00085-3004 Temozolomide Temodar 5.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 11, 1999 In Use
00085-3004-05 00085-3004 Temozolomide Temodar 5.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Nov. 2, 2012 In Use
00143-9744-01 00143-9744 Granisetron Hydrochloride Granisetron Hydrochloride 1.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Dec. 23, 2009 In Use
00143-9744-10 00143-9744 Granisetron Hydrochloride Granisetron Hydrochloride 1.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Dec. 23, 2009 In Use
00143-9745-01 00143-9745 Granisetron Hydrochloride Granisetron Hydrochloride 1.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Dec. 23, 2009 In Use
00143-9745-05 00143-9745 Granisetron Hydrochloride Granisetron Hydrochloride 1.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Dec. 23, 2009 In Use
00143-9745-10 00143-9745 Granisetron Hydrochloride Granisetron Hydrochloride 1.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Dec. 23, 2009 In Use
00143-9890-01 00143-9890 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Dec. 26, 2006 In Use
00143-9890-05 00143-9890 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Dec. 26, 2006 July 15, 2014 In Use
00143-9890-10 00143-9890 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Dec. 26, 2006 In Use
00143-9891-01 00143-9891 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous July 15, 2014 In Use
00143-9891-05 00143-9891 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Dec. 10, 2009 April 10, 2013 In Use
00143-9891-25 00143-9891 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Dec. 26, 2006 In Use
00310-0668-12 00310-0668 Olaparib Lynparza 100.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Aug. 17, 2017 In Use
00310-0668-60 00310-0668 Olaparib Lynparza 100.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Aug. 17, 2017 In Use
00310-0668-95 00310-0668 Olaparib Lynparza 100.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Sept. 1, 2022 In Use
00310-0720-10 00310-0720 Fulvestrant Faslodex 50.0 mg/mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular Nov. 1, 2010 In Use
00310-0720-25 00310-0720 Fulvestrant Faslodex 50.0 mg/mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular Nov. 1, 2010 Sept. 21, 2010 In Use
00310-0720-50 00310-0720 Fulvestrant Faslodex 50.0 mg/mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular May 20, 2002 Oct. 31, 2015 In Use
00378-1936-01 00378-1936 Lenalidomide Lenalidomide 5.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sept. 6, 2022 In Use
00378-1936-28 00378-1936 Lenalidomide Lenalidomide 5.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sept. 6, 2022 In Use
00378-1937-01 00378-1937 Lenalidomide Lenalidomide 10.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sept. 6, 2022 In Use
00378-1937-28 00378-1937 Lenalidomide Lenalidomide 10.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sept. 6, 2022 In Use
00378-1940-01 00378-1940 Lenalidomide Lenalidomide 25.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sept. 6, 2022 In Use
00378-1940-21 00378-1940 Lenalidomide Lenalidomide 25.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sept. 6, 2022 In Use
00378-1941-01 00378-1941 Lenalidomide Lenalidomide 15.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sept. 6, 2022 In Use
00378-1941-21 00378-1941 Lenalidomide Lenalidomide 15.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sept. 6, 2022 In Use
00378-6611-85 00378-6611 Isotretinoin Amnesteem 10.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Sept. 11, 2015 In Use
00378-6611-93 00378-6611 Isotretinoin Amnesteem 10.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Nov. 11, 2002 In Use
00378-6612-85 00378-6612 Isotretinoin Amnesteem 20.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Sept. 11, 2015 In Use
00378-6612-93 00378-6612 Isotretinoin Amnesteem 20.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Nov. 11, 2002 In Use
00378-6614-85 00378-6614 Isotretinoin Amnesteem 40.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Sept. 11, 2015 In Use
00378-6614-88 00378-6614 Isotretinoin Amnesteem 40.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Nov. 11, 2002 July 24, 2013 In Use
00378-6614-93 00378-6614 Isotretinoin Amnesteem 40.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Nov. 11, 2002 In Use
00409-0201-02 00409-0201 DOCETAXEL ANHYDROUS Docetaxel 10.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous March 17, 2011 In Use
00409-0201-10 00409-0201 DOCETAXEL ANHYDROUS Docetaxel 10.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous March 17, 2011 In Use
00409-0201-20 00409-0201 DOCETAXEL ANHYDROUS Docetaxel 10.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous March 17, 2011 In Use
00409-0201-25 00409-0201 DOCETAXEL ANHYDROUS Docetaxel 10.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Sept. 11, 2013 Jan. 31, 2017 In Use
00409-0201-26 00409-0201 DOCETAXEL ANHYDROUS Docetaxel 10.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Sept. 9, 2013 Jan. 31, 2017 In Use
00409-0201-27 00409-0201 DOCETAXEL ANHYDROUS Docetaxel 10.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Sept. 11, 2013 Jan. 31, 2017 In Use
00409-0302-01 00409-0302 Topotecan Topotecan 1.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Feb. 21, 2011 In Use
00409-0302-25 00409-0302 Topotecan Topotecan 1.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Sept. 24, 2013 Jan. 31, 2018 In Use
00409-0801-01 00409-0801 Pentostatin Nipent 2.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Aug. 15, 2007 In Use
00409-0801-09 00409-0801 Pentostatin Nipent 2.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Aug. 15, 2007 Oct. 1, 2016 In Use
00409-4755-01 00409-4755 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Nov. 2, 2006 April 1, 2009 In Use
00409-4755-02 00409-4755 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Aug. 29, 2007 Aug. 1, 2010 In Use
00409-4755-03 00409-4755 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Oct. 16, 2008 In Use

Found 10,000 results in 4 milliseconds — Export these results